ArcticZymes Technologies - Earnings Release 2021

ArcticZymes Technologies Successfully Upscales SAN HQ Enzyme Production

Tromsø, Norway, 26[th] March 2021 - ArcticZymes Technologies ASA (OSE: AZT)

announces it has successfully scaled-up the manufacturing of its SAN HQ enzyme

ArcticZymes Technologies´ Salt Active Nuclease High Quality (SAN HQ) enzyme

offers gene therapy and vaccine customers a more cost effective and technically

superior solution for the removal of contaminating DNA during the manufacturing

process of therapeutic viruses.

The Company entered the therapeutic segment with its SAN portfolio in 2016.

Since then, it has rapidly grown its customer base and subsequent sales. In 2020

the segment accounted for 41% of total sales revenues and demand continues to

grow. As a consequence, there was a need to transition from small-scale

fermentation production into significantly larger-scale fermenters so that

customers can receive large quantities of enzyme from a single production batch.

This successful upscaling achieved greater than a 100-fold increase in

fermentation yield and enzyme manufactured from this upscaled process will be

commercially available to our customers from early Q2.

The project was partial funded by a national grant received in May 2020 from

Innovation Norway. We are grateful to Innovation Norway for supporting the

project and recognizing its underlying value.

ArcticZymes Technologies ASA, CEO, Jethro Holter said:

"The upscaling of SAN HQ is core to ensure continuity of supply to our customers

as we mutually grow business together."

For more information, please contact:

ArcticZymes Technologies

CEO, Jethro Holter Tel: +47 46 85 91 46

CFO, Børge Sørvoll Tel: +47 95 29 01 87 [email protected]

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the

development, manufacturing and commercialization of novel recombinant enzymes

for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Listed on the Oslo Stock Exchange since 2005 originally under the [Biotec]

ticker, as Biotec Pharmacon. The company rebranded as ArcticZymes Technologies

in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at

the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large

portfolio of patents.

For more information, please visit the website: www.arcticzymes.com.

AI assistant